Skip to content

EV / sales at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
2.1×+0.6×
Guardant Health logo
Guardant HealthGH
11.8×+4.3×
Biodesix, Inc. logo
Biodesix, Inc.BDSX
+0.1×
Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
41.1×
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
1.5×-0.1×
Personalis, Inc. logo
Personalis, Inc.PSNL
9.8×+6.5×

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Calculated from Lucid Diagnostics’s reported figures.

Based on the most recent quarter.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's EV / sales?
Lucid Diagnostics (LUCD) reported EV / sales of 33× in Q1 2026.
How has Lucid Diagnostics's EV / sales changed year-over-year?
Lucid Diagnostics's EV / sales increased by 22.6% year-over-year, from 27× to 33×.
What is the long-term trend for Lucid Diagnostics's EV / sales?
Over 3 years (2022 to 2025), Lucid Diagnostics's EV / sales has grown at a -33.7% compound annual growth rate (CAGR), from 80.4× to 23.4×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.